Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

MTAP Deletion: early-phase trial registry

1 of 1 indexed MTAP Deletion trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

MTAP Deletion: 1 US clinical trial tracked, 1 recruiting.

MTAP Deletion is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Tango Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition mtap-deletion

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

MTAP Deletion (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near MTAP Deletion

MTAP Deletion lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for MTAP Deletion on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. MTAP Deletion is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on MTAP Deletion records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

gemcitabine/nab-paclitaxel Drug
1 trials
RMC-9805 Drug
1 trials
TNG462 Drug
1 trials
RMC-6236 Drug
1 trials
mFOLFIRINOX Drug
1 trials

US sites by state

Facility locations filed on MTAP Deletion trials. A trial with sites in several states counts in each.

Virginia 1 trials
Texas 1 trials
New York 1 trials
Nebraska 1 trials
Minnesota 1 trials
Massachusetts 1 trials
Indiana 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this MTAP Deletion page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MTAP Deletion condition card totals 1 registered trials; most-linked intervention gemcitabine/nab-paclitaxel; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.